Objective To analyze the research hotspots,frontiers,and trends in clinical randomized controlled trials(RCTs)on acupuncture-moxibustion for post-stroke shoulder-hand syndrome(SHS)over the past decade using bibliometric and knowledge mapping methods.Methods The clinical RCTs on acupuncture-moxibustion for post-stroke SHS from five Chinese and English databases were retrieved,including CNKI,Wanfang,VIP,PubMed,and Web of Science(WOS).CiteSpace and VOSviewer were employed for analysis,and visualized knowledge maps were generated.Results A total of 1 226 Chinese and 20 English articles were included,with both reaching publication peaks in 2021.The top three institutions in terms of output were Huguosi Traditional Chinese Medicine Hospital Affiliated to Beijing University of Chinese Medicine,The Second Affiliated Hospital of Heilongjiang University of Chinese Medicine,and Heilongjiang University of Chinese Medicine.The most prolific author was Song Fengjun,while Pei Jian had the highest centrality.The five most frequently used keywords were shoulder-hand syndrome,stroke,acupuncture-moxibustion,rehabilitation training,and joint mobility.Emerging research topics included activities of daily living,limb function,and range of motion.Conclusion Clinical research on acupuncture-moxibustion for post-stroke SHS holds significant developmental potential.Strengthening international collaboration to explore therapeutic mechanisms is recommended,and researchers should continue optimizing treatment protocols to enhance the quality of clinical evidence.

BackgroundAs a high prevalence disorder， schizophrenia has caused significant burden to family and society due to the impairment of occupational and social function. Currently， the dominant vocational training model in China follows a paternalistic， clinician-led decision-making approach. Although it improves patients' social function to some extent， it undermines their autonomy and treatment adherence. Therefore， it is urgently necessary to explore a new intervention method to enhance treatment compliance and social function in patients. ObjectiveTo explore the impact of shared decision-making oriented vocational training on social function in hospitalized schizophrenia patients， so as to provide references for rehabilitation interventions. MethodsA total of 68 patients diagnosed with schizophrenia according to the International Classification of Diseases， tenth edition （ICD-10） criteria were consecutively enrolled from January to June 2024 at The Third People's Hospital of Wenjiang Distric， Chengdu. Participants were randomly allocated into the research group （n=34） and the control group （n=34） using a random number table method. Both groups received routine rehabilitation training， while the research group received shared decision-making oriented vocational training for 12 weeks， 2 times a week for 2 hours each time. Before and at the 4^th and 12^th week of intervention， two groups were evaluated by General Self-Efficacy Scale （GSES）， Stigma Scale for Mental Illness （SSMI）， Scale of Social function of Psychosis Inpatients （SSFPI） and Inpatient Psychiatric Rehabilitation Outcome Scale （IPROS）. ResultsA total of 63 participants completed the study， with 30 cases in the research group and 33 cases in the control group. Repeated measures ANOVA revealed statistically significant time effects and interaction effects in both groups for GSES， SSMI， SSFPI and IPROS scores （F=20.451， 16.022； 26.193， 12.944； 23.957， 5.023； 11.776， 3.985， P<0.05 or 0.01）， while no significant group effects were observed （F=0.188， 0.742， 1.878， 0.474， P>0.05）. At the 12^th week of intervention， there were statistically significant differences in GSES， SSMI， SSFPI and IPROS scores between the two groups. ConclusionShared decision-making oriented vocational training may help to improve social function in patients with schizophrenia. ［Funded by 2023 Chengdu Medical Research Project （number， 2023468）］

Objective:To investigate the therapeutic effect of Brucea javanica oil emulsion combined with chemotherapy for advanced lung squamous cell carcinoma.Methods:A retrospective cohort study was conducted. The clinical data from 120 patients with lung squamous cell carcinoma at stage Ⅳ in Shanxi Province Cancer Hospital between January 2019 and December 2020 were retrospectively analyzed. According to the treatment regimens, all patients were divided into Brucea javanica oil emulsion combined with chemotherapy group (the observation group, 60 cases) and chemotherapy alone group (the control group, 60 cases). Immune function, efficacy, and chemotherapy-related adverse effects were compared between the 2 groups before and after treatment.Results:Among 120 patients, there were 77 males and 43 females, with the age of (67±7) years. There were no statistically differences in basic information between the 2 groups (all P > 0.05). The proportion of CD4 + cells and the ratio of CD4 + to CD8 + in the observation group after treatment increased compared to those before treatment, while the proportion of CD8 + decreased (all P < 0.001). In the control group, the proportions of CD3 +, CD4 +, NK cells decreased after treatment (all P < 0.001). There were no statistically significant differences in the T cell subsets between the 2 groups before treatment (all P > 0.05); after treatment, the proportions of CD3 +, CD4 +, NK cells and the ratio of CD4 + to CD8 + in the observation group were all higher than those in the control group, and the proportion of CD8 + cells was lower than that in the control group (all P < 0.001). The disease control rate (DCR) in the observation group was higher than that in the control group [73.3% (44/60) vs. 55.0% (33/60)], and the difference was statistically significant ( χ2 = 4.39, P = 0.036). The median progression-free survivals (PFS) time was 7.833 months (95% CI: 6.927-8.739 months), 5.433 months (95% CI: 3.878-6.988 months), and the difference was statistically significant ( χ2 = 4.84, P = 0.028). The incidence of leukopenia was 38.3% (23/60), 60.0% (36/60), respectively in the observation group and the control group ( χ2 = 5.64, P = 0.018); the incidence of thrombocytopenia was 21.7% (13/60), 38.3% (23/60), respectively in the observation group and the control group ( χ2 = 3.97, P = 0.046). Conclusions:Brucea javanica oil emulsion combined with chemotherapy can improve immune function, increase DCR, and reduce myelosuppression of patients with advanced lung squamous cell carcinoma.

Objective:To investigate the therapeutic effect of Brucea javanica oil emulsion combined with chemotherapy for advanced lung squamous cell carcinoma.Methods:A retrospective cohort study was conducted. The clinical data from 120 patients with lung squamous cell carcinoma at stage Ⅳ in Shanxi Province Cancer Hospital between January 2019 and December 2020 were retrospectively analyzed. According to the treatment regimens, all patients were divided into Brucea javanica oil emulsion combined with chemotherapy group (the observation group, 60 cases) and chemotherapy alone group (the control group, 60 cases). Immune function, efficacy, and chemotherapy-related adverse effects were compared between the 2 groups before and after treatment.Results:Among 120 patients, there were 77 males and 43 females, with the age of (67±7) years. There were no statistically differences in basic information between the 2 groups (all P > 0.05). The proportion of CD4 + cells and the ratio of CD4 + to CD8 + in the observation group after treatment increased compared to those before treatment, while the proportion of CD8 + decreased (all P < 0.001). In the control group, the proportions of CD3 +, CD4 +, NK cells decreased after treatment (all P < 0.001). There were no statistically significant differences in the T cell subsets between the 2 groups before treatment (all P > 0.05); after treatment, the proportions of CD3 +, CD4 +, NK cells and the ratio of CD4 + to CD8 + in the observation group were all higher than those in the control group, and the proportion of CD8 + cells was lower than that in the control group (all P < 0.001). The disease control rate (DCR) in the observation group was higher than that in the control group [73.3% (44/60) vs. 55.0% (33/60)], and the difference was statistically significant ( χ2 = 4.39, P = 0.036). The median progression-free survivals (PFS) time was 7.833 months (95% CI: 6.927-8.739 months), 5.433 months (95% CI: 3.878-6.988 months), and the difference was statistically significant ( χ2 = 4.84, P = 0.028). The incidence of leukopenia was 38.3% (23/60), 60.0% (36/60), respectively in the observation group and the control group ( χ2 = 5.64, P = 0.018); the incidence of thrombocytopenia was 21.7% (13/60), 38.3% (23/60), respectively in the observation group and the control group ( χ2 = 3.97, P = 0.046). Conclusions:Brucea javanica oil emulsion combined with chemotherapy can improve immune function, increase DCR, and reduce myelosuppression of patients with advanced lung squamous cell carcinoma.

Humans ; China/epidemiology* ; SARS-CoV-2 ; COVID-19

ObjectiveTo identify high-risk factors and high-risk process of nosocomial infection， and then take targeted prevention and control measures to improve nosocomial infection management. MethodsWe identified and determined the risk factors associated with nosocomial infection by using an expert brainstorming method， and then conducted risk assessment of the factors in the outcomes and process by using a semi-quantitative method. ResultsA total of 31 experts participated in the risk factor assessment. Risk assessment scores showed that nosocomial infection due to multi-drug resistant bacteria was the highest risk in the outcomes of nosocomial infection. Lack of isolation for airborne/droplet transmission， needle/sharp instrument injury， inadequate identification of infection risk and response measures in construction engineering， and insufficient implementation of infection control system were extremely high risk factors in the process of nosocomial infection. ConclusionPrevention and control should be strengthened on multi-drug resistant bacteria and catheter-related infections. The role of multidisciplinary team （MDT） in the prevention and control of nosocomial infection should be enhanced in medical practice. Risk assessment may facilitate the resource allocation and improve hand hygiene behavior.

In the past ten years, the research and application of microbiome has continued to increase. The microbiome has gradually become the research focus in the fields of life science, environmental science, and medicine. Meanwhile, many countries and organizations around the world are launching their own microbiome projects and conducting a multi-faceted layout, striving to gain a strategic position in this promising field. In addition, whether it is scientific research or industrial applications, there has been a climax of research and a wave of investment and financing, accordingly, products and services related to the microbiome are constantly emerging. However, due to the rapid development of microbiome sequencing and analysis related technologies and methods, the research and application from various countries have not yet unified on the standards of technology, programs, and data. Domestic industry participants also have insufficient understanding of the microbiome. New methods, technologies, and theories have not yet been fully accepted and used. In addition, some of the existing standards and guidelines are too general with poor practicality. This not only causes obstacles in the integration of scientific research data and waste of resources, but also gives related companies unfair competition opportunity. More importantly, China still lacks national standards related to the microbiome, and the national microbiome project is still in the process of preparation. In this context, the experts and practitioners of the microbiome worked together and developed the consensus of experts. It can not only guide domestic scientific research and industrial institutions to regulate the production, learning and research of the microbiome, the application can also provide reference technical basis for the relevant national functional departments, protect the scale and standardized corporate company's interests, strengthen industry self-discipline, avoid unregulated enterprises from disrupting the market, and ultimately promote the benign development of microbiome-related industries.
China ; Consensus ; Humans ; Industry ; Microbiota

Objective To investigate the expression and clinical significance of Bcl-2/adenovirus E1B19kDa interacting protein 3 (BNIP3) in serum and cerebrospinal fluid (CSF) of patients with severe hand, foot and mouth disease (HFMD). Methods Ninety children with HFMD were classified into three groups with 30 in each group:critical group (clinical stage 3), severe group (clinical stage 2) and common group (clinical stage 1, excluding encephalitis with CSF and other examinations). Another thirty healthy children were randomly selected as the control group. The levels of BNIP3 in serum and CSF were detected before and after treatment. Moreover, serum neuro-specific enolase ( NSE) and S100B protein were also measured to analyze their correlation with BNIP3. Receiver operating characteristic ( ROC) curve was used to evaluate the prediction efficiency of BNIP3 for the severity of HFMD. Results The levels of serum BNIP3, S100B protein and NSE in the critical group were higher than those in the other three groups ( P<0. 01). CSF BNIP3 level in the critical group were significantly higher than that in the common and severe groups (P<0. 01). Serum BNIP3, S100B protein and NSE were significantly higher in the severe group than in common and control groups (P<0. 01). CSF BNIP3 was significantly increased in the severe group as compared with that in the common group (P<0. 01). After treatment, the levels of BNIP3, S100B protein and NSE in serum and BNIP3 in CSF were decreased in both critical and severe groups (P<0. 01). The lev-els of BNIP3 in serum and CSF were positively correlated with the level of S100B protein and NSE ( P<0. 01). Serum BNIP3 had the highest Youden value at the cut-off value of 3. 015μg/L, with a sensitivity of 83. 33％ and a specificity of 90. 00％, in the prediction of severe HFMD. CSF BNIP3 had the highest Youden value at the cut-off value of 1. 735 μg/L, with a sensitivity of 73. 33％ and a specificity of 93.33％, in the prediction of severe HFMD. Conclusions BNIP3 is involved in the pathological process of brain injury in children with severe HFMD. Detection of BNIP3 helps evaluate the severity and prognosis of HFMD.

Liposomes, as one of the most successful nanotherapeutics, have a major impact on many biomedical areas. In this study, we performed laser scanning confocal microscope (LSCM) and immunohistochemistry (IHC) assays to investigate the intra-tumor transport and antitumor mechanism of GE11 peptide-conjugated active targeting liposomes (GE11-TLs) in SMMC7721 xenograft model. According to classification of individual cell types in high resolution images, biodistribution of macrophages, tumor cells, cells with high epidermal growth factor receptor (EGFR) expression and interstitial matrix in tumor microenvironment, in addition, their impacts on intra-tumor penetration of GE11-TLs were estimated. Type I collagen fibers and macrophage flooded in the whole SMMC7721 tumor xenografts. Tumor angiogenesis was of great heterogeneity from the periphery to the center region. However, the receptor-binding site barriers were supposed to be the leading cause of poor penetration of GE11-TLs. We anticipate these images can give a deep reconsideration for rational design of target nanoparticles for overcoming biological barriers to drug delivery.

Objective: To investigate the expression and clinical significance of Bcl-2/adenovirus E1B19kDa interacting protein 3 (BNIP3) in serum and cerebrospinal fluid (CSF) of patients with severe hand, foot and mouth disease (HFMD). Methods: Ninety children with HFMD were classified into three groups with 30 in each group: critical group (clinical stage 3), severe group (clinical stage 2) and common group (clinical stage 1, excluding encephalitis with CSF and other examinations). Another thirty healthy children were randomly selected as the control group. The levels of BNIP3 in serum and CSF were detected before and after treatment. Moreover, serum neuro-specific enolase (NSE) and S100B protein were also measured to analyze their correlation with BNIP3. Receiver operating characteristic (ROC) curve was used to evaluate the prediction efficiency of BNIP3 for the severity of HFMD. Results: The levels of serum BNIP3, S100B protein and NSE in the critical group were higher than those in the other three groups (P<0.01). CSF BNIP3 level in the critical group were significantly higher than that in the common and severe groups (P<0.01). Serum BNIP3, S100B protein and NSE were significantly higher in the severe group than in common and control groups (P<0.01). CSF BNIP3 was significantly increased in the severe group as compared with that in the common group (P<0.01). After treatment, the levels of BNIP3, S100B protein and NSE in serum and BNIP3 in CSF were decreased in both critical and severe groups (P<0.01). The levels of BNIP3 in serum and CSF were positively correlated with the level of S100B protein and NSE (P<0.01). Serum BNIP3 had the highest Youden value at the cut-off value of 3.015 μg/L, with a sensitivity of 83.33% and a specificity of 90.00%, in the prediction of severe HFMD. CSF BNIP3 had the highest Youden value at the cut-off value of 1.735 μg/L, with a sensitivity of 73.33% and a specificity of 93.33%, in the prediction of severe HFMD. Conclusions BNIP3 is involved in the pathological process of brain injury in children with severe HFMD. Detection of BNIP3 helps evaluate the severity and prognosis of HFMD.